3Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level[J]. Kidney Int,1992,41(2) :326-333.
4Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats[J]. Hypertension, 1999,33(1 Pt 2) : 232-237.
5Sun Y, Zhang J, Zhang JQ, et al. Local angiotensin Ⅱ and transforming growth factor-β in renal fibrosis of rats [J]. Hypertension, 2000,35 (5) : 1078-1084.
6Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo[J]. Kidney Int,2000,58(3) : 1219-1227.
7McManus F, Mclnnes GT, Connell JM. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist [J]. Nat Clin Pract Endocrinol Metab, 2008,4 (1) : 44-52.
9Nagase M, Shibata S, Yoshida S, et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker[J]. Hypertension, 2006,47 (6): 1084-1093.
10Kramer AB,van der Meulen EF, Hamming I, et al. Effect of combining ACE inhibitionwith aldosterone blockade on proteinuria and renal damage in experimental nephrosis[J].Kidney Int,2007,71(5) :417-424.
二级参考文献19
1Burton CJ,Harper DJ,Bailey E,et al.Turnover of human tubular cells exposed to proteins in vivo and in vitro[J].Kidney Int,2001,59(2):507-514.
2Eddy AA.Molecular insights into renal interstitial fibrosis[J].J Am Soc Nephrol,1996,7(12):2495-2508.
3Abbate M,Zoja C,Corna D,et al.In progressive nephropathies,overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation[J].J Am Soc Nephrol,1998,9(7):1213-1224.
4Rangan GK,Wang Y,Tay YC,et al.Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats[J].Kidney Int,1999,56 (1):118-134.
5Morrissey JJ,Klahr S.Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction[J].Kidney Int,1997,52(4):926-933.
6Ruggenenti P,Perna A,Gherardi G,et al.Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria[J].Lancet,1999,354(9176):359-364.
7The GISEN Group.Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric,non-diabetic nephropathy[J].Lancet,1997,349(9069):1857-1863.
8Heart Outcomes Prevention Evaluation Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy[J].Lancet,2000,355(9200):253-259.
9Estacio RO,Jeffers BW,Gifford N,et al.Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes[J].Diabetes Care,2000,23(suppl 2):B54-64.
10Parving HH,Lehnert H,Brochner-Mortensen J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
